Streetbeat News

ASND

Ascendis Pharma A/S

Industry

Biotechnology

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Open

158.09

Mkt cap

10B

Volume

574K

High

168.97

P/E Ratio

-23.43

52-wk high

168.97

Low

158.09

Div yield

N/A

52-wk low

111.09

Er-Kim has extended its exclusive distribution agreement with Ascendis Pharma A/S to expand the commercialization of its endocrinology portfolio to Eurasian markets. This agreement involves the distribution of three rare endocrinology disease treatments.

Portfolio Pulse from

December 10, 2024 | 12:15 pm

Ascendis Pharma A/S (ASND) held its Q3 2024 earnings call, discussing financial performance and operations with key executives and analysts from major financial institutions.

Portfolio Pulse from

November 15, 2024 | 4:00 am

Ascendis Pharma has reported its third quarter 2024 financial results, highlighting the upcoming U.S. launch of YORVIPATH with availability expected by mid-January 2025. The company also reported ex-U.S. YORVIPATH revenue of €8.5 million for Q3.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

BioMarin Pharmaceutical Inc. reported strong Q3 results with EPS and sales beating expectations. However, William Blair downgraded the stock, citing skepticism about future growth from its clinical pipeline. Despite strong sales from Voxzogo, competition from Ascendis Pharma's new product poses a threat. Analysts have mixed reactions, with some lowering price targets.

Portfolio Pulse from Vandana Singh

October 30, 2024 | 6:42 pm

JP Morgan analyst Jessica Fye maintains an Overweight rating on Ascendis Pharma (NASDAQ:ASND) but lowers the price target from $180 to $174.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 11:50 am

TD Cowen analyst Yaron Werber maintains a Buy rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $157 to $160.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 5:15 pm

Ascendis Pharma (NASDAQ:ASND) has significantly outperformed the market over the past decade, with an average annual return of 51.37%. A $100 investment in ASND 10 years ago would now be worth $6,501.23, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 8:00 pm

Ascendis Pharma presented 3-year data at ASBMR 2024, demonstrating that long-term treatment with TransCon PTH normalizes bone remodeling in adults with hypoparathyroidism.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:33 pm

Ascendis Pharma (NYSE:ASND) has seen a 10.56% decrease in its short percent of float, now at 7.88%. This is higher than its peers' average of 5.70%. The decrease in short interest may indicate a shift in market sentiment.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 3:00 pm

BioMarin Pharmaceutical Inc. remains confident in its 2027 revenue target despite competition from Ascendis Pharma. Goldman Sachs maintains a Buy rating on BioMarin, highlighting potential growth from Voxzogo and external business development. BioMarin is implementing a cost transformation program to achieve its financial goals.

Portfolio Pulse from Vandana Singh

September 25, 2024 | 7:50 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.